A Thorough qtc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects

Journal of Clinical Pharmacology

Volumn 49, Issue 8, 2009, Pages 937-946

  Bloomfield, Daniel M ^a   Krishna, Rajesh ^a   Hreniuk, David ^a   Hickey, Lisa ^a   Ghosh, Kalyan ^a   Bergman, Arthur J ^a   Miller, Jutta ^a   Gutierrez, Maria J ^b   Stoltz, Randall ^c   Gottesdiener, Keith M ^a   Herman, Gary A ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Comprehensive Phase One ^*  (United States)

^c Covance GFI ^*  (United States)

Author keywords

Moxifloxacin; QTc interval; Sitagliptin

Indexed keywords

MOXIFLOXACIN; PLACEBO; SITAGLIPTIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; PR INTERVAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AZA COMPOUNDS; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRAZINES; QUINOLINES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TRIAZOLES; YOUNG ADULT;

EID: 70349277582     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337511     Document Type: Article

References (20)

1. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005 ; 48 (1). 141-151.
2. Herman GA, Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 ; 91 (11). 4612-4619.
3. Karasik A., Aschner P., Katzeff H., Davies MJ, Stein PP Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008 ; 24 (2). 489-496.
4. Nauck MA, Meininger G., Sheng D., Terranella L., Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 ; 9 (2). 194-205.
5. Xu L., Dalla Man C., Charbonnel B., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008 ; 10 (12). 1212-1220.
6. Januvia (Sitagliptin Phosphate, NDA 21995). Summary basis of approval: pharmacology review. Center for Drug Evaluation and Research, Food and Drug Administration, 2006. Available at: www.fda.gov/cder/foi/nda/2006/021995s000- PharmR.pdf. Accessed October 20, 2008.
7. ICH E14 Guidance: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Federal Register. October 20, 2005. 2005 ; 70 (202). 61134-61135.
8. Zeng W., Musson D., Fisher A., Wang A. Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006 ; 20 (8). 1169-1175.
9. Shi J., Ludden T., Melikian AP, Gastonguay M., Hinderling P. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn. 2001 ; 28 (6). 555-575. (Pubitemid 34289543)
10. Bloomfield DM, Kost JT, Ghosh K., et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008 ; 84 (4). 475-480.
11. Malhotra BK, Glue P., Sweeney K., Anziano R., Mancuso J., Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007 ; 81: 377-385.
12. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M2 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005 ; 45: 1038-1047.
13. Extramiana F., Maison-Blanche P., Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther. 2005 ; 77: 247-258.
14. Noel GJ, Goodman DB, Chien S., Solanki B., Padmanabhan M., Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004 ; 44: 464-473.
15. Zhang L., Chappell J., Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007 ; 49: 146-153. (Pubitemid 46579948)
16. Iwamoto M., Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008 ; 48 (6). 726-733.
17. Bloomfield DM, Krishna R. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates. J Clin Pharmacol. 2008 ; 48 (1). 6-8.
18. Garnett CE, Beasley N., Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 ; 48 (1). 13-18.
19. Vincent SH, Reed JR, Bergman A., et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos. 2007 ; 35 (4). 533-538.
20. Bergman A., Cote J., Yi B., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007 ; 30 (7). 1862-1864. (Pubitemid 47036366)